Vepesid - instructions for use, analogs, reviews and release forms (capsules 50 mg and 100 mg, injections in injections) of a drug for the treatment of lung, stomach, lymphogranulomatosis in adults, children, pregnancy. Composition

In this article, you can read the instructions for using the drug Vapezid. Presented are the opinions of visitors to the site - consumers of this medication, as well as opinions of doctors of specialists on the use of Vepesid in their practice. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues of Vepesid in the presence of existing structural analogues.Use for the treatment of lung cancer, breast, stomach, lymphogranulomatosis, acute myeloblastic leukemia in adults, children, as well as during pregnancy and lactation. Composition of the preparation.

Vapezid antitumor agent. It is a semisynthetic derivative of podophyllotoxin. The mechanism of action is associated with the inhibition of topoisomerase 2. Oppresses mitosis, blocks cells in the S-G2 interphase of the cell cycle, at higher doses acts in the G2 phase. Cytotoxic action against normal healthy cells is only observed when using etoposide (the active ingredient of the drug Vepesid) in high doses.

Composition

Etoposide + excipients.

Pharmacokinetics

When ingestion, etoposide is absorbed from the gastrointestinal tract. Bioavailability is on average 50%. Distribution in the cerebrospinal fluid is low and variable; the concentration in normal lung tissue is higher than in the presence of metastases in the lungs; a close level of concentrations in the tissues of primary tumors and in normal tissues of the myometrium is determined. A direct relationship between the binding coefficient of Vepesid and the albumin level in the blood plasma of healthy people and patients with cancer has been noted. Metabolised in the liver.It is excreted by the kidneys - 44-60%, with feces - up to 16%, with bile - 6% or less.

Indications

• stomach cancer (for monotherapy and as part of combination therapy);
• Ewing's sarcoma (malignant bone formation);
• Mesothelioma (neoplasm from cells of serous membranes covering the body cavity and many internal organs);
• Kaposi's sarcoma;
• neuroblastoma (malignant tumor of the sympathetic nervous system);
• breast cancer (with metastases to the liver, to the pleura);
• ovarian cancer;
• malignant neoplasm of placenta (chorion carcinoma);
• Testicular tumors;
• Hodgkin's disease (lymphogranulomatosis);
• follicular (nodular) non-Hodgkin's lymphoma;
• diffuse non-Hodgkin's lymphoma;
• acute myeloid leukemia.

Forms of release

Capsules 50 mg and 100 mg.

Concentrate for the preparation of a solution for infusions of 100 mg in 5 ml (injections in ampoules for injections).

Instructions for use and dosing regimen

Inside, on an empty stomach (you can take it with a glass of orange juice). The daily dose is 100-200 mg per 1 m2 of the body surface for 3-5 days. Then follows the period during which the drug is not applied: 4 days after taking 3 days or 2 weeks after taking it for 5 days.

Intravenously, slowly (for 30-60 minutes).The preparation should be diluted with 5% glucose solution, isotonic solution of sodium chloride or mixed solution to a concentration of less than 0.4 mg in 1 ml. Enter for 3 or 5 consecutive days of 50-100 mg per 1 m2 of body surface per day followed by a break, lasting from 2 to 3 weeks.

The exact dosage regimen is set individually, depending on the indications and stage of the disease, the status of the hematopoiesis system, the scheme of antitumor therapy.

Side effect

• leukopenia, anemia, less thrombocytopenia;
• nausea, vomiting;
• anorexia (a neuropsychic disorder manifested by an obsessive desire to lose weight, fear of obesity);
• mucositis (toxic-inflammatory disease of the oral mucosa and submucosal tissue);
• diarrhea;
• stomatitis (inflammation of the oral mucosa);
• toxic reactions from the liver;
• drowsiness, increased fatigue;
• defeat of the peripheral nervous system;
• Hyperuricemia (high uric acid in the blood);
• metabolic acidosis (violation of acid-base balance in the body);
• tachycardia (increased heart rate);
• arterial hypotension (lowering blood pressure);
• azoospermia (absence of spermatozoa in the ejaculate);
• amenorrhea (absence of menstruation during several menstrual cycles);
• chills, fever;
• bronchospasm (a decrease in the lumen of the bronchi);
• alopecia (baldness);
• anaphylactic reactions.

Contraindications

• expressed myelodepression (oppression of bone marrow hematopoiesis);
• marked violations of the liver and kidneys;
• pregnancy;
• children under 2 years;
• hypersensitivity to the components of the drug.

Application in pregnancy and lactation

Vepeside is contraindicated in pregnancy. If necessary, use during lactation should stop breastfeeding.

During treatment and within 3 months after its end, patients of childbearing age need to apply effective methods of contraception.

In experimental studies, it has been established that etoposide exerts a teratogenic and embryotoxic effect.

Use in children

Contraindicated in children under 2 years.

Use with caution in children older than 2 years.

special instructions

They are used with caution in patients with previous radiation or chemotherapy, with chicken pox, herpes zoster, infectious lesions of mucous membranes, heart rhythm disorders, increased risk of myocardial infarction, impaired liver function, diseases of the nervous system (epilepsy), chronic alcoholism, in children older than 2 years.

If the renal function is impaired, the dose of Vepeside is reduced in accordance with the values ​​of creatinine clearance.

Before and against the background of the therapy should monitor the picture of peripheral blood (the number of platelets, leukocytes, hemoglobin, differential formula). With a platelet count of less than 50,000 in 1 mm3 or neutrophils less than 500 in 1 mm3, further treatment is stopped until the cellular composition of the blood is restored.

Do not recommend the vaccination of patients and their families.

In experimental studies, it has been established that etoposide has a mutagenic effect.

Impact on the ability to drive vehicles and manage mechanisms

During treatment, Vapezid should refrain from occupations requiring increased attention and rapid psychomotor reactions.

Drug Interactions

With simultaneous use with other drugs that cause myelodepression, additive inhibition of bone marrow function is possible.

With the simultaneous use of Vepeside with cisplatin, the clearance of etoposide and the increase in its toxicity are possible.

Cyclosporine in high doses can reduce the clearance of etoposide and increase the duration of its action, with the possible increase in leukopenia.

Analogues of the drug Vepesid

Structural analogs for the active substance:

• Fins;
• Phytoside;
• Etoposide.

Analogues of the drug Vepesid on the pharmacological group (antitumor agents of plant origin);

• Abitaxel;
• Abraxan;
• Velba;
• Velbin;
• Verotecan;
• Vinblastine;
• Vinelbin;
• Winkater;
• Vincristine;
• Vinorelbine;
• Wumond;
• Gikamtin;
• Jevtan;
• Docetaxel;
• Dotserera;
• Javlor;
• Intaksel;
• Irinaks;
• Irinotecan;
• Irinotel;
• Iritin;
• Irkokam;
• Yondelis;
• Kampeter;
• Campto;
• Kanataksen;
• Kanglaite;
• Colotecan;
• Condiline;
• Fins;
• Mawerex;
• Mitotax;
• Navelbin;
• Novotaks;
• Oncodocel;
• Oncocristin;
• The paclikal;
• Paclitaxel;
• Pacifier;
• Paxen;
• Sindaxel;
• Taxiade;
• Taxol;
• Taxotere;
• Tautax;
• Topotecan;
• Phytoside;
• Cituvin;
• Aldesine;
• Etoposide;
• Yutaksan.

Response of a therapist

About the drug Vapezid can speak only with the words of patients from my site who received it with malignant tumors. Each of them complained of pronounced side effects when taking this medication. So, for example, a woman with breast cancer had marked head hair loss and constant nausea. The patient with a testicle tumor suffered a sharp decrease in blood pressure and worried about the constant inflammation of the oral mucosa. In addition, in the blood tests they registered a decrease in the level of hemoglobin and the number of leukocytes.

Similar medicines:

Other medicines: